�鶹ӰԺ

Darwin Biosciences — a CU �鶹ӰԺ spinoff and creator of the Sick Stick — has developed a rapid, portable, saliva-based COVID-19 test able to return results in 45 minutes. Thousands of tests have been deployed in community settings including public schools and universities, and regulatory approval is pending.

Current Capital Raise:��Series A
Amount: $3.5-4.5 million

OnKure is discovering and developing first-in-class and best-in-class histone deacetylase inhibitors for the treatment of cancer and cancer treatment-related neuropathies. Its��team, consisting of former Array BioPharma founding management, is focused on disrupting this important and challenging field. OKI-179, OnKure's lead clinical stage asset, has completed a phase-1 dose escalation trial at the University of Colorado and is poised to begin phase 2 signal searching trials for specific solid tumor indications. OnKure is partnering with Pfizer on one of these trials to address the Nras melanoma population.

Current Capital Raise:��Series B
Amount: $30�������������Dz�

LongPath Technologies was recognized with the 2019 Governor's Award for High-Impact Research for our collaboration with researchers at CU �鶹ӰԺ and the National Institute of Standards and Technology (NIST). The award highlights ground-breaking discoveries and innovative research from Colorado’s ecosystem of federally-funded laboratories and institutions. Dr. Greg Rieker of CU �鶹ӰԺ co-founded Longpath Technologies, a spinoff commercializing cost-effective, continuous gas leak detection. Longpath is currently preparing for commercial deployments starting in summer 2020 and are actively raising their first investment round, which will expand the commercial deployments and grow the team.

Current Capital Raise:��Series A
Amount: $2.5-4 million